— Know what they know.
/
Not Investment Advice

ABT

NYSE · USD
Abbott Laboratories
Healthcare · Medical - Devices
CEO Robert Ford Employees 115,000 R&D / revenue 6.7%
Last price
$104.88+0.19%last session
Market cap
$181.5B
P/E (TTM)
33.7x
From 52w high
−20.6%
From 52w low
+27.9%
1-year return
−17.8%
RSI 14 · vs SMA200
59.5 · +2.1%
IS score
56.6/ 100
Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.
Download full factsheet (PDF)

One year, rebased to 100

ABT   SPY   XLV (sector ETF) · weekly closes
80100120Jan 26Apr 26Jul 26Oct 26XLV 124SPY 116ABT 82

Score DNA

Each bar is a 0-100 score within the scored universe
46
Profitability
28
Growth
49
Value
60
Momentum
80
Risk (safety)
70
Quality
62
Balance sheet
72
Earnings quality

Flags

Strengths
✓ Insider buying✓ Congress buying
Warnings
None of the computed warning flags fires for ABT (Altman, Beneish, accruals, FCF, dilution).
Observations
Moat model: Weak, Efficient ScalePiotroski 5 / 9Altman Z 3.0Beta 0.594 of 4 smart-money sources active

Smart-money strip

Each disclosure source on its own window. Filings coinciding is not coordination.
INSForm 4 · 180 days
Insider open-market buys
3
$1.30M bought
Form 144 notices (12m): 12, $50.9M proposed, not confirmed sales
CONGSTOCK Act · 180 days
Congressional purchases
13
Last disclosed purchase 2026-09-18
Members disclose in ranges, 30-45 days after the trade
13F13F · quarter to 2026-06-30
Net change in institutional holders
−134
191 new holders, 281 closed
2,987 filers hold 82.5% · 1,065 added, 1,394 trimmed
ETFETF holdings · 30 days
Net funds accumulating
+292
1,520 funds adding shares
1,228 funds trimming · counts of funds, not dollars
DARKFINRA · daily
Short-sale share of off-exchange volume
40.3%
20-day avg 44.4%, 50-day avg 46.5%
Latest 4.1 pp under its 20-day average · a flow, not short interest

Key financials · FY2025

USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.
Income statement
Revenue$44.3B
Revenue growth YoY+5.7%
Gross margin55.5%
Operating income$8.0B
Operating margin18.2%
Net income$6.5B
Net margin14.7%
EPS (diluted)$3.72
Cash flow
Operating cash flow$9.6B
Capital expenditure$2.2B
Free cash flow$7.4B
FCF conversion (FCF / OCF)77.3%
Stock-based compensation$664.0M
FCF less SBC$6.7B
Buybacks$893.0M
Dividends$4.1B
Balance sheet & returns
Cash & short-term investments$8.9B
Total debt$14.1B
Net debt$5.2B
Shareholders' equity$52.8B
Goodwill & intangibles$29.6B
Debt / equity0.64
ROE (TTM)10.5%
ROIC (TTM)6.1%
Operating margin by fiscal year
21.4%FY202119.2%FY202216.1%FY202316.4%FY202418.2%FY2025
Revenue $43.1B (FY2021) to $44.3B (FY2025), a 0.7% CAGR.

Valuation

P/E (TTM)33.7x
EV / EBITDA18.5x
Price / sales3.90x
Price / FCF20.8x
FCF yield4.80%
Buyback yield0.49%
SBC / revenue1.5%
Price / book3.58x
Forward P/E FY202619.0x
Forward P/E FY202717.3x
Forward P/E FY202815.6x
Forward multiples divide today's price by Street EPS estimates. Street mean target $123.67 across 6 analysts last quarter is theirs, not ours.

ABT vs industry median

318 companies in Medical - Devices
Gross margin 56.8% 57.3% Operating margin 17.0% -22.8% Net margin 11.6% -23.0% ROIC 6.1% -5.0%
ABT (TTM)Industry median Asset turnover 0.43 vs industry 0.55 · financial leverage 2.14

Earnings delivery

Next report 2026-10-21 · consensus EPS $1.42
58%
beat rate, 7 of 12 quarters
+0.9%
median EPS surprise
3
longest beat streak
+4+0+3+4+1+0+2+0+0+0+1+2
EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2023-10-18 to 2026-07-16. Bars cap at ±60%.

Peers

Market-cap band, not the industry cohort above
CompanyMkt capP/EROENet marginRev growth12m return
ABT Abbott Laboratories $181.5B33.7x10.5%11.6%+5.7% −17.8%
MDT Medtronic Plc $121.2B23.2x10.7%15.1%+9.8% +3.0%
SYK Stryker Corporation $113.0B30.3x16.5%19.4%+8.5% −20.2%
BSX Boston Scientific Corporatio $64.3B17.9x15.5%16.7%+13.5% −54.6%
EW Edwards Lifesciences Corpora $49.9B49.8x9.5%13.9%+14.6% +19.2%
DXCM DexCom, Inc. $32.5B33.2x38.5%19.0%+15.5% —
GILD Gilead Sciences, Inc. $193.7Bn/m-20.6%—+5.5% —
PFE Pfizer Inc. $168.6B39.1x5.0%-1.6%−0.2% —
12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.

Recent 8-K filings

2026-08-20Regulation FD; Other Events; Exhibits
2026-07-16Earnings Release; Exhibits
2026-04-27Officer/Director Change; Bylaws Amendment; Shareholder Vote; Exhibits
2026-04-17Other Events; Exhibits
2026-04-16Earnings Release; Exhibits
2026-03-23Other Events; Exhibits

Context

Shares outstanding1,730,383,296
Free float99.4%
Institutional ownership82.5%
Beta0.59
Dividend yield2.40%
Last dividend$0.63 on 2026-10-15
50 / 200-day average$105.93 / $102.91
Large-cap Healthcare median P/E29.7x

Full factsheet

The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (Weak).

Read it in the browser Download (PDF)

All fundamentals · 140 measures in 13 categories

Percentile = where ABT sits among 61 scored companies in Medical - Devices (0 = lowest value, 100 = highest). It is a position, not a grade.
ValuationProfitability (TTM)Returns on capitalGrowthMargin history & stabilityLiquidity (latest quarter)Leverage & solvency (latest quarter)EfficiencyCash flow & earnings qualityDividends & buybacksScores & forensic checksPer shareSize (TTM)

Valuation

MeasureABTIndustry medianIndustry percentileSector median
P/E (TTM) 33.5x 25.7x
67th		 27.6x
PEG (P/E ÷ 3-yr EPS CAGR) 18.41 1.33
100th		 1.28
Price / sales 3.9x 3.3x
62nd		 3.7x
Price / book 3.6x 3.5x
54th		 3.6x
Price / tangible book —
Price / free cash flow 20.8x 26.8x
39th		 21.2x
Price / operating cash flow 18.3x 19.5x
40th		 17.1x
Enterprise value $208.5B $2.0B
100th		 $2.5B
EV / sales 4.5x 3.5x
65th		 3.8x
EV / EBITDA 19.0x 18.6x
53rd		 16.2x
EV / EBIT 26.1x 24.7x
58th		 23.0x
EV / free cash flow 23.9x 27.6x
39th		 24.6x
Earnings yield 3.0% -0.7%
70th		 -0.3%
FCF yield 4.8% 1.9%
77th		 1.7%
Operating cash flow yield 5.5% 3.4%
72nd		 2.9%
Graham number (per share) $45.32 $42.90
56th		 $26.70

Profitability (TTM)

MeasureABTIndustry medianIndustry percentileSector median
Gross margin 56.8% 63.7%
38th		 65.1%
EBITDA margin 23.5% 9.3%
82nd		 6.6%
Operating margin 17.0% 4.0%
83rd		 3.5%
EBIT margin 17.2% 1.4%
82nd		 2.4%
Net margin 11.6% -1.7%
80th		 0.3%
NOPAT margin 12.3% 0.1%
73rd		 2.7%
FCF margin 18.7% 3.0%
88th		 4.3%
Operating cash flow margin 21.3% 8.5%
83rd		 7.1%
R&D / revenue 6.8% 10.1%
34th		 12.4%
SG&A / revenue 28.9% 46.6%
15th		 37.9%
Stock comp / revenue 1.5% 3.5%
30th		 4.5%
Effective tax rate 27.8% 21.0%
90th		 21.0%

Returns on capital

MeasureABTIndustry medianIndustry percentileSector median
ROE (on average equity) 10.7% -1.7%
71st		 0.8%
ROA 5.6% -1.1%
70th		 -0.3%
ROIC 7.3% 1.1%
63rd		 5.5%
ROCE 8.8% 1.6%
70th		 2.3%
Return on tangible assets 8.3% 1.0%
73rd		 1.7%
Cash ROIC (OCF / invested capital) 12.7% 7.0%
68th		 9.7%
Gross profitability (GP / assets) 24.2% 36.4%
22nd		 29.9%
ROIC, 3-yr average 10.8% -1.0%
80th		 2.6%
ROIC, 5-yr average 13.9% -0.4%
82nd		 3.2%
ROE, 5-yr average 17.9% -4.8%
85th		 -4.9%
Incremental ROIC -22.2% 19.9%
33rd		 17.2%

Growth

MeasureABTIndustry medianIndustry percentileSector median
Revenue growth (TTM YoY) 8.1% 11.5%
38th		 10.5%
Revenue growth (QoQ) 12.8% 7.8%
70th		 7.2%
Revenue CAGR, 3 yr 5.0% 11.6%
23rd		 10.7%
Revenue CAGR, 5 yr 3.0% 12.8%
12th		 12.1%
Gross profit CAGR, 3 yr 9.9% 12.8%
38th		 10.6%
Operating income CAGR, 3 yr 9.4% 12.0%
40th		 11.7%
Net income growth (TTM YoY) -61.2% 8.7%
8th		 17.5%
Net income CAGR, 3 yr 1.7% 13.1%
30th		 11.3%
EPS growth (TTM YoY) -61.0% 7.8%
8th		 19.2%
EPS CAGR, 3 yr 1.8% 14.5%
25th		 14.0%
EPS CAGR, 5 yr -2.6% 9.1%
20th		 8.1%
FCF growth (TTM YoY) 28.7% 16.8%
57th		 18.6%
FCF CAGR, 3 yr 16.7% 32.2%
31st		 15.4%
Operating cash flow CAGR, 3 yr 9.9% 18.3%
32nd		 11.9%
Book value CAGR, 3 yr 11.3% 5.2%
67th		 2.1%
Dividend CAGR, 3 yr 2.5% 2.5%
50th		 2.2%
Sustainable growth rate 2.3% 10.9%
4th		 12.2%

Margin history & stability

MeasureABTIndustry medianIndustry percentileSector median
Gross margin, 3-yr average 53.4% 64.5%
26th		 62.6%
Operating margin, 3-yr average 16.9% 4.3%
87th		 1.0%
Net margin, 3-yr average 19.2% -5.8%
94th		 -2.6%
FCF margin, 3-yr average 16.1% 2.8%
91st		 3.2%
Revenue stability (0-1) 0.69 0.90
17th		 0.80
Earnings stability (0-1) 0.04 0.30
6th		 0.37
Margin stability (0-1) 0.95 0.96
40th		 0.93

Liquidity (latest quarter)

MeasureABTIndustry medianIndustry percentileSector median
Cash & short-term investments $5.6B $184.9M
98th		 $330.9M
Net cash (− = net debt) −$27.0B −$37.3M
0th		 $8.4M
Working capital $6.7B $318.0M
97th		 $381.1M
Current ratio 1.38 3.35
8th		 3.02
Quick ratio 0.97 2.33
12th		 2.51
Cash ratio (cash + ST investments / current liabilities) 0.31 0.87
22nd		 1.43
Defensive interval (days) 279 days 324 days
43rd		 415 days

Leverage & solvency (latest quarter)

MeasureABTIndustry medianIndustry percentileSector median
Total debt $32.6B $263.7M
100th		 $289.1M
Debt / equity 0.64 0.54
58th		 0.45
Net debt / equity 0.53 0.28
65th		 −0.13
Debt / assets 29.9% 27.9%
53rd		 24.4%
Debt / capital 38.9% 35.1%
58th		 31.1%
Debt / EBITDA 2.98 2.56
58th		 2.62
Net debt / EBITDA 2.46 2.08
58th		 1.42
Interest coverage (EBIT / interest) 12.6x 0.4x
87th		 2.1x
Cash interest coverage 15.5x 3.2x
90th		 3.6x
Debt payback (years of OCF) 3.3 yrs 3.4 yrs
49th		 2.7 yrs
Liabilities / assets 52.6% 49.8%
57th		 49.8%
IS credit model rating A+ — —
Implied credit spread (bps) 125 225
28th		 225

Efficiency

MeasureABTIndustry medianIndustry percentileSector median
Asset turnover 0.48 0.60
23rd		 0.56
Fixed asset turnover 3.64 4.84
24th		 4.87
Inventory turnover 2.8 1.8
78th		 2.7
Receivables turnover 5.6 6.4
32nd		 6.4
Days sales outstanding 65 days 57 days
68th		 57 days
Days inventory outstanding 129 days 207 days
22nd		 136 days
Days payables outstanding 83 days 59 days
75th		 59 days
Cash conversion cycle (days) 112 days 214 days
20th		 70 days
Capex / revenue 2.5% 3.6%
29th		 2.6%
Capex / depreciation 0.40 0.67
21st		 0.55
Operating expense ratio 43.8% 57.4%
20th		 56.5%

Cash flow & earnings quality

MeasureABTIndustry medianIndustry percentileSector median
Operating cash flow / net income 1.83 1.65
70th		 1.61
FCF / net income 1.61 1.30
78th		 1.36
FCF / operating cash flow 88.0% 63.6%
83rd		 81.2%
Capex / operating cash flow 12.0% 36.4%
17th		 18.8%
Accruals ratio -4.6% -5.2%
52nd		 -5.4%
Sloan accruals ratio -7.5% -1.3%
25th		 -1.3%
Earnings quality score (0-1) 1.00 1.00
48th		 0.75

Dividends & buybacks

MeasureABTIndustry medianIndustry percentileSector median
Dividend yield 2.4% 0.0%
97th		 0.0%
Dividend per share (TTM) $2.52 $0.00
97th		 $0.00
Payout ratio (dividends / net income) 78.5% 0.0%
100th		 0.0%
Dividends / FCF 48.9% 0.0%
89th		 0.0%
Dividend growth (YoY) 7.7% 4.0%
67th		 4.5%
Buyback yield 1.0% 0.0%
73rd		 0.0%
Shareholder yield (dividends + buybacks) 3.4% 0.0%
87th		 0.0%
Share count change (YoY) -0.5% 1.4%
32nd		 2.0%
Buybacks, last 5 years $5.8B $0
100th		 $0

Scores & forensic checks

MeasureABTIndustry medianIndustry percentileSector median
IS score 57 41
67th		 46
IS profitability 46 20
63rd		 22
IS growth 28 60
11th		 60
IS value 49 39
72nd		 39
IS momentum 60 67
32nd		 67
IS risk (safety) 80 65
52nd		 80
IS quality 70 49
62nd		 49
IS balance sheet 62 50
65th		 55
IS earnings quality 72 56
72nd		 56
IS cash flow 74 32
82nd		 41
Piotroski F-score (0-9) 5 6
35th		 5
Altman Z-score 3.0 3.0
52nd		 3.2
Beneish M-score −2.69 −2.67
41st		 −2.62
Ohlson O-score −8.73 −7.26
28th		 −7.16
IS credit score 76 62
72nd		 62

Per share

MeasureABTIndustry medianIndustry percentileSector median
EPS, diluted (TTM) $3.11 −$0.07
75th		 −$0.03
Book value per share $29.32 $10.13
82nd		 $7.10
Tangible book per share −$0.40 $2.24
28th		 $1.91
Revenue per share $26.73 $12.68
73rd		 $9.38
FCF per share $5.00 $0.62
85th		 $0.46
Operating cash flow per share $5.68 $1.25
78th		 $0.93
Cash per share $3.21 $2.47
57th		 $3.51

Size (TTM)

MeasureABTIndustry medianIndustry percentileSector median
Market cap $181.5B $1.6B
100th		 $2.4B
Revenue $46.6B $815.1M
100th		 $770.2M
EBITDA $11.0B $83.1M
100th		 $56.1M
Net income $5.4B −$7.2M
100th		 −$3.3M
Free cash flow $8.7B $38.8M
100th		 $41.2M
Total assets $109.2B $1.1B
100th		 $1.3B
Shareholders' equity $51.1B $496.6M
100th		 $568.4M
Employees 115,000 1,800
100th		 1,086

Insider transactions, last 6 months

Form 4 · most recent 12
DateInsiderTypeSharesPriceValueOwned after
2026-09-30Stratton John G
Director
 Award / grant 397——14,499
2026-09-30Gonzalez Patricia Paola
Director
 Award / grant 333——6,331
2026-09-30Conroy Kevin T
Director
 Award / grant 318——551
2026-09-30Ahuja Nita
Director
 Award / grant 318——771
2026-09-30Roman Michael F
Director
 Award / grant 381——7,166
2026-09-23Conroy Kevin T
Director
 Tax withholding 52,507$103.99$5.5M81,230
2026-09-02Mccoy John A. Jr.
VICE PRESIDENT AND CONTROLLER
 Open-market sale 27$109.54$2,95824,549
2026-09-01Boudreau Philip P
EVP AND CFO
 Tax withholding 388$110.36$42,82070,784
2026-09-01Mccoy John A. Jr.
VICE PRESIDENT AND CONTROLLER
 Tax withholding 52$110.36$5,73924,576
2026-08-25Ford Robert B
Director, CHAIRMAN AND CEO
 Option exercise 151,869$44.40$6.7M458,330
2026-08-25Ford Robert B
Director, CHAIRMAN AND CEO
 Option exercise 246,963$59.94$14.8M705,293
2026-08-25Ford Robert B
Director, CHAIRMAN AND CEO
 Open-market sale 218,535$115.57$25.3M486,758

Shares acquired vs disposed, by month

acquired disposed · all Form 4 types
MarAprMayJunAugSep

By transaction type, 6 months

TypeDirectionFilingsSharesValue
Award / grantAcquired2546,307$1.4M
DiscretionaryAcquired214,223$1.3M
DiscretionaryDisposed112$1,296
Open-market buyAcquired314,200$1.3M
Open-market saleDisposed4404,709$46.9M
Option exerciseAcquired2398,832$21.5M
Option exerciseDisposed2398,832$21.5M
Tax withholdingDisposed553,776$5.6M
—Disposed10—
Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.

Form 144 notices

12 months: 12 notices · 447,292 shares · $50.9M
FiledFilerShares proposedEst. proceeds
2026-09-02John A. Mccoy, Jr.27$2,957
2026-08-25Robert B. Ford398,832$46.2M
2026-08-11Louis H. Morrone5,850$642,506
2026-05-15Robert J. Alpern7,587$646,791
A Form 144 is notice of a proposed sale, not a confirmed one.

Congress trades

12 months: House 72 trades (24 purchases) · Senate 0 (0 purchases)
TradedMemberChamberTypeAmountDisclosed
2026-09-18Gilbert CisnerosHousePurchase$1,001 - $15,0002026-10-13
2026-09-18Gilbert CisnerosHousePurchase$1,001 - $15,0002026-10-12
2026-09-04Ro KhannaHousePurchase$1,001 - $15,0002026-10-09
2026-07-30Rich McCormickHouseSale$1,001 - $15,0002026-08-17
2025-02-24Shelley Moore CapitoSenateSale (Partial)$1,001 - $15,0002025-03-06
2025-02-24Shelley Moore CapitoSenateSale (Partial)$1,001 - $15,0002025-03-05
2025-02-24Shelley Moore CapitoSenateSale (Partial)$1,001 - $15,0002025-03-05
2025-01-08Markwayne MullinSenateSale (Full)$1,001 - $15,0002025-01-31
STOCK Act disclosures, in ranges, filed up to 45 days after the trade.

Largest 13F holders

Quarter to 2026-06-30, the latest most managers have filed
ManagerSharesValue% of shares out
BlackRock, Inc.152,563,476$13.8B8.82%
VANGUARD CAPITAL MANAGEMENT LLC113,750,994$10.3B6.57%
STATE STREET CORP80,926,234$7.3B4.68%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC59,522,592$5.4B3.44%
Sixth Street Partners Management Company, L.P.59,522,592$5.4B3.44%
VANGUARD PORTFOLIO MANAGEMENT LLC49,017,866$4.4B2.83%
GEODE CAPITAL MANAGEMENT, LLC39,219,337$3.5B2.27%
Capital Research Global Investors36,908,990$3.3B2.13%
Capital International Investors34,654,113$3.1B2.00%
MORGAN STANLEY25,348,430$2.3B1.46%
NORGES BANK23,354,911$2.1B1.35%
PRICE T ROWE ASSOCIATES INC /MD/22,787,202$2.1B1.32%
FRANKLIN RESOURCES INC18,805,880$1.7B1.09%
BANK OF AMERICA CORP /DE/17,672,543$1.6B1.02%
GOLDMAN SACHS GROUP INC16,760,070$1.5B0.97%

Institutional ownership by quarter

2023-092026-0682.5%
% of shares held by 13F filers
2023-092026-062,987
Number of 13F filers holding

Holder changes by quarter

QuarterHoldersOwnershipNewIncreasedReducedClosed
2026-06-302,98782.5%1911,0651,394281
2026-03-313,12179.0%1841,1181,443295
2025-12-313,29382.1%3491,1511,358165
2025-09-303,18377.9%1721,1981,333129
2025-06-303,19779.2%1851,3251,228119
2025-03-313,17878.9%2751,1361,357119
2024-12-313,07577.5%3341,1311,170106
2024-09-302,90475.0%1901,0821,202127
2024-06-302,87575.8%1511,1451,187155
2024-03-312,91875.0%1911,1681,142128
2023-12-312,89475.0%3459631,22594
2023-09-302,68874.5%1479801,160159

Schedule 13D / 13G filers

FiledFormFiler% of classShares
2026-03-26SCHEDULE 13G/AThe Vanguard Group0.0%0
2025-12-03SCHEDULE 13G/AThe Vanguard Group10.1%174,894,079
Required above 5% of a class; 13G is the passive form.

ETFs with the largest holding

ETFWeight in fundHolding value
VITSX0.23%$5.4B
VSMPX0.23%$5.4B
VTSAX0.23%$5.4B
VTI0.23%$5.4B
VFIAX0.26%$4.5B
VFFSX0.26%$4.5B

Share structure

Shares outstanding1,730,383,296
Float1,719,845,262
Free float99.4%

Income statement

Fiscal years, USD
FY2021FY2022FY2023FY2024FY2025
Revenue$43.1B$43.7B$40.1B$42.0B$44.3B
Cost of revenue$19.9B$21.3B$20.1B$20.6B$19.7B
Gross profit$23.2B$22.3B$20.0B$21.3B$24.6B
R&D$2.7B$2.9B$2.7B$2.8B$3.0B
SG&A$11.3B$11.1B$10.9B$11.7B$12.4B
Operating income$9.2B$8.4B$6.4B$6.8B$8.0B
EBITDA$12.2B$11.9B$10.6B$10.8B$11.6B
Pretax income$8.2B$8.3B$6.7B$7.0B$8.5B
Income tax$1.1B$1.4B$941.0M−$6.4B$1.9B
Net income$7.1B$6.9B$5.7B$13.4B$6.5B
EPS, diluted$3.94$3.91$3.27$7.64$3.72
Diluted shares1.8B1.8B1.7B1.7B1.7B

Balance sheet

FY2021FY2022FY2023FY2024FY2025
Cash & short-term investments$10.2B$10.2B$7.3B$8.0B$8.9B
Receivables$6.5B$6.2B$6.6B$6.9B$7.9B
Inventory$5.2B$6.2B$6.6B$6.2B$6.5B
Total current assets$24.2B$25.2B$22.7B$23.7B$26.0B
PP&E, net$10.1B$10.3B$11.3B$11.7B$12.9B
Goodwill & intangibles$36.0B$33.3B$32.5B$29.8B$29.6B
Total assets$75.2B$74.4B$73.2B$81.4B$86.7B
Accounts payable$4.4B$4.6B$4.3B$4.2B$4.2B
Total current liabilities$13.1B$15.5B$13.8B$14.2B$16.5B
Long-term debt$17.3B$14.5B$13.6B$12.6B$10.8B
Total liabilities$39.2B$37.5B$34.4B$33.5B$33.9B
Shareholders' equity$36.0B$36.9B$38.8B$47.9B$52.8B

Cash flow statement

Outflows are negative
FY2021FY2022FY2023FY2024FY2025
Net income$7.1B$6.9B$5.7B$13.4B$6.5B
Depreciation & amortization$3.5B$3.3B$3.2B$3.2B$3.1B
Stock-based compensation$640.0M$685.0M$644.0M$673.0M$664.0M
Change in working capital−$771.0M−$1.5B−$2.5B−$9.2B−$803.0M
Operating cash flow$10.5B$9.6B$7.3B$8.6B$9.6B
Capital expenditure−$1.9B−$1.8B−$2.2B−$2.2B−$2.2B
Free cash flow$8.6B$7.8B$5.1B$6.4B$7.4B
Investing cash flow−$2.0B−$1.7B−$3.1B−$2.3B−$2.4B
Net debt issued / repaid−$248.0M−$699.0M−$2.5B−$537.0M−$1.6B
Buybacks−$2.3B−$3.8B−$1.2B−$1.3B−$893.0M
Dividends paid−$3.2B−$3.3B−$3.6B−$3.8B−$4.1B

Ratio history

Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end
FY2021FY2022FY2023FY2024FY2025
Gross margin53.9%51.1%50.0%50.9%55.5%
Operating margin21.4%19.2%16.1%16.4%18.2%
Net margin16.4%15.9%14.3%31.9%14.7%
FCF margin20.1%17.9%12.6%15.1%16.7%
ROE20.6%19.1%15.2%31.1%13.1%
ROIC17.7%15.7%11.7%23.9%10.6%
ROA9.6%9.3%7.8%17.3%7.8%
Debt / equity0.540.490.410.320.29
Interest coverage21.0x27.4x10.5x12.6x21.2x
Current ratio1.851.631.641.671.58
Revenue growth+24.5%+1.3%−8.1%+4.6%+5.7%
EPS growth+57.9%−0.4%−17.2%+134.4%−51.3%
P/E at year end32.9x26.2x32.3x14.5x33.6x
EV / EBITDA at year end19.9x15.9x18.3x18.6x19.3x
FCF yield at year end3.72%4.30%2.73%3.28%3.38%
Dividend payout45.3%47.7%62.1%28.6%63.1%

Revenue by segment

FY2021FY2022FY2023FY2024FY2025
Medical Devices$14.4B$14.7B$16.9B$19.0B$21.4B
Diagnostic Products$15.6B$16.6B$10.0B$9.3B$8.9B
Nutritional Products$8.3B$7.5B$8.2B$8.4B$8.5B
Established Pharmaceutical Products$4.7B$4.9B$5.1B$5.2B$5.5B

Revenue by region · FY2025

UNITED STATES$17.1B · 40%
Non-US$16.0B · 37%
D [E]$2.8B · 6%
C [N]$1.9B · 4%
I [N]$1.9B · 4%
C [H]$1.9B · 4%
J [P]$1.5B · 3%

Street estimates by fiscal year

Next report 2026-10-21 · consensus EPS $1.42 · these are analysts' numbers, not ours
Fiscal yearRevenue (mean)Revenue rangeEPS (mean)EPS rangeAnalystsP/E on mean EPS
2026$50.3B$50.2B – $50.4B$5.52$5.48 – $5.571719.0x
2027$54.7B$53.6B – $55.3B$6.07$6.01 – $6.191717.3x
2028$58.5B$53.8B – $59.8B$6.73$4.55 – $7.661115.6x

Reported vs expected, every quarter on file

ReportedEPS expectedEPS actualEPS surpriseRevenue expectedRevenue actualRevenue surprise
2026-07-16$1.28$1.31+2.3%$12.5B$12.6B+0.6%
2026-04-16$1.14$1.15+0.9%$11.0B$11.2B+1.5%
2026-01-22$1.50$1.500.0%$11.8B$11.5B−2.9%
2025-10-15$1.30$1.300.0%$11.4B$11.4B−0.2%
2025-07-17$1.26$1.260.0%$11.1B$11.1B+0.5%
2025-04-16$1.07$1.09+1.9%$10.4B$10.4B−0.5%
2025-01-22$1.34$1.340.0%$11.0B$11.0B−0.5%
2024-10-16$1.20$1.21+0.8%$10.6B$10.6B+0.8%
2024-07-18$1.10$1.14+3.6%$10.4B$10.4B+0.1%
2024-04-17$0.95$0.98+2.6%$9.9B$10.0B+0.8%
2024-01-24$1.19$1.190.0%$10.2B$10.2B+0.6%
2023-10-18$1.10$1.14+3.6%$9.6B$10.1B+5.5%
2023-07-20$1.04$1.08+3.8%$9.7B$10.0B+2.9%
2023-04-19$0.98$1.03+5.1%$9.6B$9.7B+1.1%
2023-01-25$0.90$1.03+14.4%$9.7B$10.1B+4.4%
2022-10-19$0.91$1.15+26.4%$9.6B$10.4B+7.9%
2022-07-20$1.13$1.43+26.5%$10.3B$11.3B+9.0%
2022-04-20$1.47$1.73+17.7%$11.0B$11.9B+8.2%
2022-01-26$1.21$1.32+9.1%$11.1B$11.5B+3.4%
2021-10-20$0.95$1.40+47.4%$9.4B$10.9B+15.7%
2021-07-22$1.01$1.17+15.8%$9.4B$10.2B+8.2%
2021-04-20$1.33$1.32−0.8%$10.8B$10.5B−2.8%
2021-01-27$1.35$1.45+7.4%$9.9B$10.7B+8.0%
2020-10-21$0.90$0.98+8.9%$8.2B$8.9B+7.7%

Off-exchange (dark pool) volume, weekly

FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)
0.906-151.206-220.806-291.007-062.207-131.407-201.507-270.908-030.908-101.008-171.208-241.208-31
Week ofNotionalSharesTrades
2026-08-31$1.2B10,873,131154,467
2026-08-24$1.2B10,500,250135,538
2026-08-17$962.7M8,463,518138,699
2026-08-10$852.9M7,729,751123,310
2026-08-03$893.9M8,389,701141,556
2026-07-27$1.5B13,935,139196,914

Short-sale share of off-exchange volume

daily 20-day average
07-2310-1540.3%
DateShort shareShort volumeTotal volume
2026-10-1540.3%1,515,3733,757,156
2026-10-1440.1%986,8602,460,218
2026-10-1334.7%1,326,2513,821,502
2026-10-1243.0%1,036,7702,409,842
2026-10-0937.6%1,069,7902,843,847
2026-10-0850.5%1,333,9362,639,661
2026-10-0724.8%704,8882,841,030
2026-10-0650.6%1,406,7342,780,465
2026-10-0554.5%1,842,2953,382,606
2026-10-0239.4%1,257,2683,189,150
A daily flow measure from FINRA, not short interest.

Seasonality

Average return by calendar month
+1.4Jan+0.5Feb-0.0Mar+0.9Apr+0.9May+1.3Jun+3.2Jul-0.2Aug+0.3Sep+0.9Oct+1.8Nov+1.7Dec
MonthAvg returnUp yearsYears
Jan+1.4%65%20
Feb+0.5%60%20
Mar−0.0%52%21
Apr+0.9%60%20
May+0.9%55%20
Jun+1.3%60%20
Jul+3.2%75%20
Aug−0.2%60%20
Sep+0.3%50%20
Oct+0.9%45%20
Nov+1.8%65%20
Dec+1.7%70%20
History, not a forecast.

Indicators

as of 2026-10-16
RSI 1459.5
MFI49.8
ADX24.6
Stochastic %K / %D90.7 / 84.8
Williams %R-8.7
CCI136
TSI / signal-6.0 / -19.0
Chaikin money flow0.08
ATR$2.38
Bollinger width10.2%
Volume vs 20-day avg0.90x
SupertrendUp

Moving averages and bands

level (price vs level)
SMA 20$100.64 (+4.2%)
SMA 50$105.74 (−0.8%)
SMA 200$102.68 (+2.1%)
EMA 21$101.71 (+3.1%)
EMA 50$102.59 (+2.2%)
EMA 200$105.04 (−0.2%)
Bollinger upper$105.76 (−0.8%)
Bollinger lower$95.52 (+9.8%)
Parabolic SAR$96.93 (+8.2%)
Open the live chart, 110+ indicators

About Abbott Laboratories

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

https://www.abbott.com

Key executives

NameTitlePayBorn
Robert FordExecutive Chairman & CEO$4.4M1974
Elizabeth CushmanExecutive Vice President, General Counsel & Secretary$2.5M1970
Lisa D. EarnhardtExecutive Vice President & Group President of Medical Devices$2.4M1970
Philip BoudreauChief Financial Officer & Executive Vice President of Finance$2.1M1973
Christopher J. ScogginsExecutive Vice President of Diabetes Care$2.1M1970
Daniel Gesua Sive SalvadoriExecutive Vice President and Group President of Established Pharmaceuticals & Nutritional Products$1.5M1979
Melissa BrotzSenior Vice President of Global Marketing & External Affairs——
Michael ComillaVice President of Investor Relations.——

Executive pay, latest proxy

ExecutiveYearSalaryStock awardsIncentiveTotal
Robert B. Ford , Chairman of the Board and Chief Executive Officer2025$1.5M$8.8M$2.0M$24.2M
Philip P. Boudreau , Executive Vice President, Finance and Chief Financial Officer2025$974,231$3.0M$1.1M$9.1M
Lisa D. Earnhardt , Executive Vice President and Group President, Medical Devices2025$924,231$2.5M$1.3M$8.1M
Hubert L. Allen , Former Executive Vice President, General Counsel and Secretary2025$524,019$2.1M$447,500$7.0M
Christopher J. Scoggins , Executive Vice President, Diabetes Care2025$859,502$1.7M$1.1M$6.6M
Daniel G. Salvadori , Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products2025$924,231$2.2M$388,200$6.5M

Employees

103k2018107k2019109k2020113k2021115k2022114k2023114k2024115k2025

Dividends

Ex-dateAmountPaid
2026-10-15$0.632026-11-16
2026-07-15$0.632026-08-17
2026-04-15$0.632026-05-15
2026-01-15$0.632026-02-13
2025-10-15$0.592025-11-17
2025-07-15$0.592025-08-15
2025-04-15$0.592025-05-15
2025-01-15$0.592025-02-14

Moat model

Weak · Efficient Scale · 2026-06-30
Cost advantage68
Intangibles51
Switching costs27
Network effect60
Efficient scale85
Our component scores (0-100) and overall 54.9; a model of the business, not a call on the stock.
InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms